A Phase I/II Study of Carfilzomib as a Replacement for Multiple Myeloma Patients Failing Bortezomib-containing Regimens.

Trial Profile

A Phase I/II Study of Carfilzomib as a Replacement for Multiple Myeloma Patients Failing Bortezomib-containing Regimens.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Bendamustine; Dexamethasone; Doxorubicin liposomal
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biomira USA; Oncotherapeutics.
  • Most Recent Events

    • 29 Feb 2016 Results of phase I part of this study (n=44) published in the Investigational New Drugs
    • 13 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 Sep 2015, according to to ClinicalTrials.gov record.
    • 13 Apr 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top